Thrombosis and Hemostasis Biomarkers Market – By Product, By Test Location, By Test Type, By Application, By End Use, Global Forecast, 2024 to 2032

Major players in the industry include Abbott Laboratories, ARUP Laboratories, Biomedica Diagnostics, BioMerieux, Cincinnati Children's Hospital Medical Center, Cleveland Clinic Laboratories, Diazyme Laboratories, F. Hoffmann-La Roche, HORIBA, Mayo Clinic Laboratories, and QuidelOrtho.

The U.S. thrombosis and hemostasis biomarkers market is expected to grow at a 5.8% CAGR, reaching USD 3 billion by 2032, driven by high rates of cardiovascular disease.

The global thrombosis and hemostasis biomarkers industry was valued at USD 5.2 billion in 2023 and is estimated to grow at a CAGR of over 5.8% from 2024 to 2032, driven by rising incidences of cardiovascular and clotting disorders.

The reagents and consumables segment dominated the market with USD 3.3 billion in 2023 due to their pivotal role in diagnostic and research applications, including assay kits, chemicals, buffers, and other essential reagents.